





Ver. 20241231



The Future of Biotechnology **MEDIPOST**

Life-Changing **INNOVATIONS**

Creating a better tomorrow through Innovative Stem Cell Technology



MEDIPOST LOGO MOTIF

DNA carries the genetic information of life. Like many life forms who flourish as they inherit the genetic traits of the parents, MEDIPOST's DNA technology and therapeutics contain various facets that play a fundamental role in creating a diverse visual language and consistent brand image for the MEDIPOST Company.

Each branch represents the six core values (compassion, trust, value creation, challenge, innovation, and passion) and is interpreted as a DNA sequence of distinct patterns that is used for MEDIPOST's unique language.



Better Tomorrow through A Innovation Cell Therapy

“The most important thing is to make an innovative business model. MEDIPOST is one among many Korean companies that can measure up against the Apple Corporation of the United States.”

Raffi Amit (Professor of Management at the Wharton School),
‘the master of global creative management’
at GEW International Conference, 2010

“MEDIPOST has technology for developing stem cell therapy and an organic business structure based on cord blood. It is one of the most promising stem cell companies in the world that carries out active R&D every year.”

HSBC Global Research Strategy Report,
Disruptive Technology, 2013



About Us

MEDIPOST, a global player in the field of stem cells

MEDIPOST puts the value of life first and continues to prioritize health and wellness through ceaseless R&D focusing on stem cell research so that everyone can live a healthy and happy life. MEDIPOST's creates a healthy and happy world with the goal of becoming the world's No. 1 global company in stem cell therapeutics.

86

Number of registered patents
in Korea and overseas

38

Number of national R&D
grants received in Korea

313,484 units

Number of private cord blood
units stored

46%

Percentage of
R&D staff

(as of Dec 2024)

MEDIPOST's Vision

MEDIPOST aspires to improve the quality of lives for patients with unmet medical needs through rigorous research, development and commercialization in the field of stem cell therapeutics and regenerative medicine.

VISION

Global leader in biotechnology & regenerative medicine
with innovative stem cell technologies

MISSION

Providing comprehensive, stem cell-based solutions for health, longevity and improving the
quality of lives of patients with unmet medical needs

CORE VALUE

- Customer & Patient-Oriented : Care for Lives and Value Creation for customers and patients
- Talent-Oriented : Challenging unmet medical needs through Innovation and Passion

CEO MESSAGE

By giving hope to patients with incurable diseases, MEDIPOST will become **the No.1 global stem cell company**

Established in 2000 and driven by our mission and vision, MEDIPOST aims to become the No.1 global stem cell company by developing stem cell therapy, giving new hope to patients with incurable diseases.

MEDIPOST has been leading the advancement of stem cell therapy with the market approval of CARTISTEM, the world's first stem cell therapy. Even when the birth rate rapidly decreased, MEDIPOST enhanced the value of personalized cord blood and expanded its Korean market share through a patient awareness to become the No. 1 cord blood bank business.

MEDIPOST is entering an inflection point as it aims to become the leader of the global cell therapy market by launching stem cell therapies that will change the world. MEDIPOST will grow as an innovative company that differentiates itself from competitors by entering the global cell and gene therapy CDMO market based on the world's best stem cell production knowledge that has been developed for the past 20 years.

MEDIPOST is now transitioning from a Korea's representative bio-company to a global leader in bioengineering. MEDIPOST will write a new history as the 'No.1 stem cell company' and a 'top-tier cell and gene therapy CDMO company'. We promise to grow as a company that prioritizes human dignity and value of life while contributing to the enhancement of the health and quality of life for all people.

CEO and President Wonil Oh M.D.,Ph.D.



Company History

2000
⋮
2005

A new paradigm for treating incurable diseases with stem cell technology.

- Launched CELLTREE® cord blood bank for private cord blood banking service (2000)
- Launched R&D Center for commercialization of stem cell therapeutics (2001)
- Received the Best Venture Company Award by the Federation of Korean Industries (2002)
- Appointed as a Lead Cord Blood Bank Operator by the Cell Application Project Research Group of the Ministry of Science and Technology, Korea (2003)
- Received the Bronze Tower Award of Industrial Service Merit, Korea (2005)
- Cleared Phase 1/2 clinical trial approval of CARTISTEM® for the treatment of knee cartilage damage (2005)
- Successful Initial Public Offering(IPO) on KOSDAQ (2005)

2006
⋮
2010

Tackling unmet medical needs with cutting-edge stem cell technologies.

- Appointed as technical advisor for the establishment of Seoul Municipal Public Cord Blood Bank (2006)
- Established Good Manufacturing Practice(GMP) cell manufacturing facility in Seoul (2006)
- Became Korea's first overseas supplier of public cord blood unit for transplantation (2008)
- Received the Innovation Award in biotechnology sector, at the Asia Innovation Conference (2009)
- Received the nationwide Outstanding Achievement in R&D Award by the Ministry of Trade, Industry and Energy of Korea (2009)
- Cleared Phase 1 clinical trial approval of PNEUMOSTEM® for the preventive treatment of Bronchopulmonary Dysplasia(BPD) (2010)
- Completed Korea's first clinical trial for the cerebral palsy treatment using cord blood units (2010)

2011
⋮
2015

Expanding the future of regenerative medicine on to the global stage.

- Invited to present keynote address at the '7th World Stem Cell Summit, California USA' (2011)
- Cleared Phase 1/2 clinical trial approval of CARTISTEM® by the US-FDA - a first US-FDA IND (2011)
- Received Biologics License Application (BLA) of CARTISTEM® in Korea - world's first approval of allogeneic stem cell product (2012)
- Achieved first export of stem cell product - CARTISTEM® from Korea to Hong Kong (2012)
- Awarded the Grand Prize (MFDS Minister's Award) at the 1st Korea New Drug Awards (2013)
- Cleared Phase 1/2 clinical trial approval of PNEUMOSTEM® by the US-FDA (2014)
- Achieved 200,000 cumulative units of private cord blood storage at CELLTREE® (2015)

2016
⋮
Present

Leading the next generation research and development with advanced stem cell platform technology.

- Cleared Phase 1 clinical trial approval of 'SMUP-IA-01' for injectable treatment for knee OA in Korea (2019)
- Approval of Phase 3 clinical trials for CARTISTEM® by the Ministry of Health, Labour and Welfare (MHLW), Japan (2021)
- Established the subsidiary company 'IMMUNIQUE', developing the cord blood-derived immune cell therapy (2021)
- Acquired the shares of OmniaBio Inc, CDMO producing Gene-modified Cell therapies in Canada (2022)
- Received OJSM award for MEDIPOST's 5-year follow-up of CARTISTEM® phase 3 clinical trial patients (2022)
- Awarded the 'Leading Companies in Materials, Parts, and Equipment' by the Ministry of Trade, Industry and Energy (2023)
- End of Phase 2 clinical trials for injectable drug for knee OA 'SMUP-IA-01' in Korea (2024)

A world without limits, A life without limits

MEDIPOST brings our dreams into reality by being the leader in creating new therapies from stem cells that improve the quality of life for all.



Main Business Area



Stem cell therapy

Development of new cord blood-derived stem cell therapy

MEDIPOST developed and successfully commercialized CARTISTEM[®], an allogeneic cord blood-derived stem cell therapy, by obtaining market approval from MFDS in January 2012. CARTISTEM[®] is a treatment of repetitive and/or traumatic cartilage degeneration including Degenerative Osteoarthritis(OA) without age limit, which is commercially sold in the market in Korea and has completed phase 1 and 2a clinical trials in the United States. MEDIPOST is also conducting clinical trials of PNEUMOSTEM[®], a treatment for bronchopulmonary dysplasia, and SMUP-IA-01, an injectable treatment for osteoarthritis, as well as all-phase clinical trials of various diseases including acute respiratory distress syndrome (ARDS).



CDMO

Contract Development and Manufacturing of Cell and Gene Therapy

MEDIPOST's knowledge and experience in cell therapy development can result in quick clinical trials and commercialization. MEDIPOST owns GMP facilities in Korea and North America that meet the latest GMP regulations and offers the best service through high-quality human resources who have rich experience in the development of stem cell therapy and various service options. MEDIPOST has provided quality control test results of a cell and gene therapy product that meets GMP-related regulations, KP, USP, and EP based on years of hands-on experience and outstanding experts.



Cord blood bank

CELLTREE[®], Korea's representative cord blood bank

Cord blood is blood collected from the umbilical cord of newborns. It is a valuable life resource that can treat incurable diseases of babies or families by implanting cord blood stem cells. CELLTREE cord blood bank boasts unparalleled expertise and a strict management system in the extraction, storage, and implantation of cord blood stem cells based on MEDIPOST's advanced stem cell technology. CELLTREE cord blood bank is also recognized for its expertise and technology as Korea's representative cord blood bank with the No.1 market share and No. 1 supply of therapeutic implantation.



Nutritional supplements

MOVITA[®], a customized nutrition solution for families

MOVITA provides a smart nutrition solution according to the lifecycle for the health and happiness of families and their individual family members. It systematically analyzes and programs the functions of the supplement based on the age, gender, and life-phase of the individuals to protect the health of the family safely and thoroughly using the best ingredients. The CEO, a former doctor, formulated the solution based on the Dietary Reference Intakes for Koreans, ensuring safety for both mothers and babies.


MEDIPOST STEM CELL THERAPY

MEDIPOST's cutting-edge stem cell technology treats intractable diseases

1st Generation Cord Blood-derived Stem Cell Products



CARTISTEM®
Treatment of knee cartilage defects including for patients with Knee Osteoarthritis



PNEUMOSTEM®
Preventive Treatment for Bronchopulmonary Dysplasia(BPD)

2nd Generation Cord Blood-derived Stem Cell Products



SMUP-IA-01
Intra-articular Injectable treatment for osteoarthritis



SMUP-IV-01
Intra-venous infusion treatment for diabetic nephropathy




Scan the QR code and you will be directed to the page with detailed information.

Future of biotechnology and regenerative medicine, the stem cells

Stem cells are undifferentiated cells with the ability to differentiate into various cell types making up the tissues within the body. Stem cells can restore damaged tissues and bodily functions through self-replication, differentiation and/or the secretion of various growth factors.

Healing power of newborn cells, MEDIPOST's cord blood-derived stem cell products

The core strengths of MEDIPOST's stem cell products lies within the most primitive and youngest stem cells derived from umbilical cord blood of the new born babies. Umbilical cord blood is fetal blood found in the umbilical cord of a newborn baby and is the source of the most primitive form of 'adult' stem cells due to the vitality around the time of beginning of life. Umbilical cord blood stem cells are the youngest among all types of adult stem cells and retain the characteristics of stem cells with an excellent regenerative capacity.



SMUP-Cell : Next-generation stem cell technology platform

Advanced Small cell(SM) selection combined with proprietary culture method for retaining and enhancing optimum stem cell characteristics throughout the repeated subculture steps, enable manufacturing of Ultra Potent(UP) cells through large-scale culture expansion.

Next generation cord blood-derived mesenchymal stem cells with higher efficiency and lower cost

MEDIPOST CDMO SERVICE

MEDIPOST owns GMP facilities in Korea and North America that meet the latest GMP regulations and offers the best service through high-quality personnel who have rich experience in the development of stem cell therapy and various service options.

Quality System

MEDIPOST guarantees the quality of all manufacturing processes and test methods of products manufactured by MEDIPOST. MEDIPOST complies with the guidelines and requirements of regulatory institutions and operations follow high quality standard that meet the latest GMP regulations. MEDIPOST periodically conducts verification for the process robustness in manufacturing products and consistency of a product quality. Also, MEDIPOST continuously conducts GMP training for GMP employees about a quality documentation and a quality risk management to ensure the high quality standard of products manufactured in MEDIPOST's GMP facilities.



CDMO Service Introduction

Scan the QR code and you will be directed to the page with detailed information.

CDMO Service

MEDIPOST's know-how in cell therapy development can result in quick clinical trials and commercialization. MEDIPOST owns GMP facilities in Korea and North America that meet the latest GMP regulations and offers the best service through high-quality personnel who have extensive experience in the development of stem cell therapy and various service options.



Quality Control Service

MEDIPOST provides the quality control test results of cell and gene therapy that meets GMP-related regulations, KP, USP, and EP based on years of hands-on experience and outstanding experts. Even without investment costs, we have been able to cost-effectively use test equipment and have excellent manpower at MEDIPOST to provide the best results.



Global CDMO

MEDIPOST offers its clients, who are planning overseas clinical trials through the CDMO facility at OmniaBio in North America, cell therapy production technology that meets global standards and an 'all-in-one package' including the development, manufacturing, quality testing, and licensing support of advanced biopharmaceuticals.



CELLTREE Cord Blood Bank

THE FIRST PROMISE – The first promise for the Healthy Future of My Child

“Once-in-a-Lifetime Opportunity”, the Value of Umbilical Cord Blood Storage.

By taking advantage of the once-in-a-lifetime storage opportunity of umbilical cord blood stem cells which are only available for collection at birth, parents can have their baby’s umbilical cord blood stored and made them available at a later date for umbilical cord blood stem cell transplants, if the baby or any family member develops an intractable disease later in life. We believe that even with only a 1% chance, the importance of life must be preserved. Thus, we continue to pursue the value of umbilical cord blood.

Korea’s Most-Trusted Cord Blood Bank, CELLTREE®

CELLTREE® is a brand name of MEDIPOST’s umbilical cord blood bank. MEDIPOST has successfully commercialized the world’s first regulatory-approved umbilical cord blood-derived mesenchymal stem cell product - CARTISTEM®.

A ‘Treasury’ of Stem Cells, the value of Cord Blood

Umbilical cord blood, the fetal blood from the umbilical cord of newborn infants, is rich in both the Hematopoietic Stem Cells (HSCs) which can create all blood components, as well as the Mesenchymal Stem Cells (MSCs) which may develop to become tissues such as cartilage, bones and the muscle. This is why umbilical cord blood is widely recognized as a valuable life-resource that can regenerate damaged tissue functions.



First-in-Class Technology

CELLTREE®, supported by excellence in storage technology has been proven by numerous transplantations performed on patients with multiple types of disease conditions.

The number of CELLTREE® Transplantations :
563units (as of Dec 2024)

· Unrelated transplantation (468units)


· Autologous-transplantation (78units)

· Related transplantation (17units)

First-in-Class Credibility

CELLTREE®, the umbilical cord blood bank recognized by the largest number of families with the top market-share.

Number of cord blood units stored under CELLTREE® :
313,484units (as of Dec 2024)



Based on data from the Ministry of Health and Welfare, Korea (December 2016)

MOVITA Nutritional Supplements

First Gift for Your Loved Ones

MOVITA PRIDE & PROMISE

MOVITA provides a smart nutrition solution according to the lifecycle for the health and happiness of families and their individual family members. It systematically analyzes and programs the functions of the supplement based on the age, gender, and life-phase of the individuals to protect the health of the family safely and thoroughly using the best ingredients. The CEO, a former doctor, formulated the solution based on the Dietary Reference Intakes for Koreans, ensuring safety for both mothers and babies.

Customized nutritional supplement solution, MOVITA®

MOVITA is a nutritional supplement brand for providing smart nutrition solutions for the health and happiness of families. It systematically analyzes and programs the functions by age and lifecycle of customers, and provides a family nutrition solution based on the best ingredients.



Nutrition for families

Customized nutrition for the whole family



Dinokiki Probiotics

Contains lactobacillus reuteri derived from breast milk



Gyno-pHresh healthy female probiotics

Vagina health functionality approved by MFDS
Individually-approved vaginal lactobacillus



Hiddink's joint 100

Guus Hiddink's secrete for maintaining healthy joints



Nutrition for pregnant women

Customized nutrition by pregnant stage for mothers and babies



Mothers Balance 1

Essential nutritional supplements for expected mothers



Mothers Balance 2

Nutritional support for the well-being of the mother and solid growth of the unborn baby throughout the mid-term pregnancy



Mothers Balance 3

Nutritional support for safe childbirth and healthy breast-feeding

Global Networks

Global Leader in Stem Cell Therapeutics

As a global leader in biotechnology with cutting-edge Technologies in Stem Cell Therapeutics, MEDIPOST continues to innovate and challenge to tackle unmet medical needs.

MEDIPOST GLOBAL MAP



● Overseas

· MEDIPOST, INC.
245 Main St, Cambridge,
MA 02142, USA

· OmniaBio Inc (CGT CDMO)
175 Longwood Rd. S Suite 201A Hamilton,
ON L8P 0A1, Canada

· MEDIPOST K.K.
Masumoto Bldg, 5F, 1-7-6 Toranomom,
Minato-ku Tokyo, 105-0001 Japan

📍 Cord Blood Transplant

U.S.A. / CANADA
SWEDEN / AUSTRALIA

○ Patent Right


U.S.A. / ENGLAND / SWITZERLAND / SINGAPORE
SPAIN / CHINA / ITALY / CANADA / JAPAN
AUSTRALIA / FRANCE / HONG KONG / SWEDEN
NETHERLANDS / INDIA / MEXICO / GERMANY
AUSTRIA / BELGIUM / DENMARK / FINLAND
IRELAND / NORWAY / POLAND / PORTUGAL
TURKIYE

△ Clinical Trial

U.S.A. / JAPAN

Corporate Social Responsibility(CSR)

Based on our corporate philosophy to respect the value of human lives, MEDIPOST is engaged in sponsorship and charity activities



MEDIPOST values its corporate philosophy : Respect for Life

Based on our corporate philosophy to respect the value of human lives, MEDIPOST is engaged in sponsorship and charity activities for funding biotechnology research activities for finding cures for the intractable diseases and supporting families in need.



Major Activities

Supporting Storage Cost

Providing Cord Blood Bank services for multi-child families



Research & Clinical Sponsorships

Basic research funding at the Seoul National University College of Medicine




Operation of donated cord blood bank

Life sharing through the supply of donated cord blood



Surgical Sponsorship

Free cord blood transplantation for children with cerebral palsy



Free Cord Blood Storage

Free Cord Blood Storage for Siblings of Children with Leukemia



Financial Sponsorship

Sponsoring treatment of underprivileged patients with pediatric cancer and other incurable diseases

